# June 26: Dr. Kim Jessup, The Good, The Bad and The Ugly for Clinical Markers: Possibilities For the Future

**SYNOPSIS:**

Markers are becoming more important in NCI-supported clinical trials. These trials are becoming increasingly oriented toward precision medicine. Unfortunately, Program Staff do not have access to a database that tracks such markers to make sure their use can be managed. The Center for Coordinating Clinical Trials (CCCT) was mandated to create the Clinical Trials Reporting Project (CTRP) to coordinate tracking all elements of the clinical trials. CTRP now contains nearly 7,000 trials with roughly half of them including markers on all patients; 12% of said trials have integral markers that are essential for performance of the trial, e.g., mutations for eligibility for targeted therapies. The presentation will cover the CTRP Marker database and its potential as a resource for staff and potentially the public.

Session details...

**BIO:**

Kim Jessup, M.D. is a surgical oncologist who joined the Cancer Diagnosis Program at NCI as Chief of the Diagnostics Evaluation Branch in 2006. This branch facilitates the transition of discovery-based markers into in-vitro diagnostics that are used in clinical trials. As part of this effort, Dr. Jessup helped with the creation of the Markers Database in the Clinical Trials Reporting Project as well as the creation of electronic case-report forms (eCRFs) for pharmacodynamic assays for the Experimental Therapeutics-Clinical Trials Network. He also collaborates with the FDA to standardize assays for clinical trials and assists investigators in navigating the requirements for Investigational Device Exemption. In 25 years of practice, he has focused on the multidisciplinary treatment of GI and breast cancer, melanoma, and soft tissue/skeletal sarcomas in several different academic settings. In addition, he led a research effort studying the mechanisms that underpin hepatic metastasis by human colorectal carcinoma and identified two distinct roles for the marker carcinoembryonic antigen in modulating inflammatory responses and promoting metastasis. Currently, Dr. Jessup is a Principal Investigator in the Laboratory of Experimental Carcinogenesis in the NCI Center for Cancer Research. His research targets a novel embryonic retrogene that drives cancer stem cells in metastatic human colorectal carcinoma.

**SUMMARY:**

Topic: The Good, The Bad and The Ugly for Clinical Markers: Possibilities For the Future

Speaker: Dr. Kim Jessup

Date: Wednesday, June 26, 2013

Time: 11 AM – 12 PM

Dr. Jessup will give his presentation in person at 2nd Floor East, Room 032-034 at the NCI Shady Grove Building on Medical Center Drive. The presentation will also be available via WebEx.

Presentation: A screen cast of the presentation will be available for viewing after the event here on our Speaker Series Videos page on the NCI's CBIIT Speaker Series YouTube Playlist .

*About the NCI CBIIT Speaker Series:*

The National Cancer Institute (NCI) Center for Biomedical Informatics and Information Technology (CBIIT) Speaker Series is a bi-weekly knowledge-sharing forum featuring both internal and external speakers on topics of interest to the biomedical informatics and research communities. For additional information, including past speaker series presentations, visit the CBIIT Speaker Series page.

Questions? Please email us at NCICBIITcomms@mail.nih.gov.

Individuals with disabilities who need reasonable accommodation to participate in this program should contact the Office of Space and Facilities Management (OSFM) at 240-276-5900 or the Federal TTY Relay number 1-800-877-8339.